Stefan Wohlfeil previously held the position of Chief Medical Officer at TRIN Pharma. The change in management takes place at a time, where TRIN Pharma is moving its lead molecule TRIN 2755 into Phase I clinical development.

Dr. Rudolf Reiter, who held the position previously in addition to his role as CEO of Ergonex, will now focus entirely on his responsibility for Ergonex. Rudolf Reiter commented: "I am pleased to pass the leadership of TRIN Pharma on to Stefan Wohlfeil who has the right expertise to drive the clinical development of TRIN 2755. This will allow me to direct my full attention to Ergonex and the development of Terguride."

Stefan Wohlfeil said: "I am excited to take over from Rudolf Reiter at a time where our lead molecule is entering clinical development. I would like to thank Rudolf for his excellent work and many contributions during the build-up phase of TRIN Pharma."

TRIN Pharma starts phase I clinical trial of TRIN 2755 in solid tumors

Appenzell, Switzerland, November 09, 2009 / b3c newswire / -
TRIN Pharma GmbH, specializing in the development of small molecule drugs for tumor treatment, announced today that BfArM, the German regulatory authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumors. The trial will be conducted at two very experienced clinical sites in Germany, Westdeutsches Tumorzentrum in Essen and Tumor Biology Center in Freiburg.

TRIN 2755 is based on a new chemistry with solid IP platform. Preclinical experiments have demonstrated excellent activity of TRIN 2755 in xenograft models of human malignant melanoma, breast and colon cancer, including drug resistant tumors. The vast majority of animals treated with TRIN 2755 reached complete and stable remission at well tolerated doses.

TRIN 2755, the company's lead molecule in a series of novel triazene analogs, exerts rapid metabolic clearance while at the same time tolerability was very good in early toxicology studies.

Stefan Wohlfeil, CEO of TRIN Pharma said: "We are very excited about the start of the clinical development of our lead molecule. We believe that TRIN 2755 has a high likelihood of showing clinical benefit and to become an important part of anti-cancer therapy."